The trial is designed to assess the safety and effectiveness of Avisi Technologies' investigational VisiPlate device in ...

A non-bioabsorbable stent intended to be implanted in a coronary artery or ... pressure gradients, valve areas, shunt flows, vascular resistance, diastolic filling period or systolic ejection period.

Using intravascular imaging (IVI) to guide stent implantation during complex stenting procedures is safer and more effective ...

Patients who have a stent implanted to open a blocked coronary artery face dual risks of developing blood clots and of having excessive bleeding in the months following the procedure. While routine ...

Currently, all drug-eluting stents (DES), used to treat blocked heart arteries, are priced at Rs 35,000. (Image Credits: Pixabay) Gujarat government has introduced different prices for stents to ...

Avisi Technologies, a clinical-stage ophthalmic device company, today announced encouraging six‐month interim results from the VITA trial evaluating its VisiPlate® device, an ultrathin, multichannel ...

Avisi Technologies' VisiPlate® shunt is a unique design made of a patented metamaterial that has been designed to be non-fibrotic and is many times thinner than a human hair. The device is both ...

Anaconda Biomed announced the enrollment and treatment of the first U.S. patient in a clinical trial of its ANA Funnel ...